Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials

Jin-Tai Yu 1, Wei Xu 2, Chen-Chen Tan 2, Sandrine Andrieu 3, John Suckling 4, Evangelos Evangelou 5, An Pan 6, Can Zhang 7, Jianping Jia 8, Lei Feng 9, Ee-Heok Kua 9, Yan-Jiang Wang 10, Hui-Fu Wang 2, Meng-Shan Tan 2, Jie-Qiong Li 2, Xiao-He Hou 2, Yu Wan 2, Lin Tan 2, Vincent Mok 11, Lan Tan 2, Qiang Dong 1, Jacques Touchon 12, Serge Gauthier 13, Paul S Aisen 14, Bruno Vellas 15

ABSTRACT

Background Evidence on preventing Alzheimer’s disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention.

Methods Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised.

Results A total of 44 676 reports were identified, and 243 OPSSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).

Interpretation Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.

INTRODUCTION

An unequivocal downtrend in the prevalence and incidence of dementia was recently reported and associated with earlier population-level investment (eg, improved education and vascular health), strengthening the necessity for primary prevention.

METHODS

Search strategy and selection criteria
We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2009 guidelines. PubMed,
Cognitive neurology

Figure 1 Flow chart showing literature selection for OPSs (figure 1A) and RCTs (figure 1B) and map depicting studies eligible for systematic review (figure 1C). A total of 243 OPSs (figure 1A) and 153 completed RCTs (figure 1B) were finally included. 243 OPSs from 17 countries on four continents (Europe accounting for 43%, North America 41%, Asia 14% and Latin America 2%) reported the association of 134 modifiable risk factors with risk of clinical Alzheimer’s-type dementia (83% used all AD, 13% probable AD and 11% pure AD) diagnosed by NINCDS-ADRDA criteria in populations with various racial backgrounds (68% white, 14% Asian descent, 13% mixed race), sources (84% community, 6% institution, 10% mixed source) and baseline cognitive statuses (82% free of dementia, 16% cognitively normal, 2% unclear). A total of 153 published RCTs from five continents (North America accounting for 45%, Europe 36%, Australia 9%, Asia 7% and Latin America 3%) reported the effects of 15 types of interventions on AD (7%), dementia (16%) and cognitive function (85%) in selected participants, including elderly subjects (37%), high-risk group (35%) or cognitively impaired (28%) (figure 1C).

EMBASE and CENTRAL were searched using the terms “Alzheimer’s”, “Alzheimer”, “dementia”, and “risk” for OPS and “Alzheimer”, “cognitive”, “cognition”, “prevent”, and “prevention” for RCT up to 1 March 2019. Bibliographies of relevant literature and records in ClinicalTrials.gov and AlzRisk database were hand-searched in case of omission. The inclusion criteria were as follows: (1) an OPS exploring the association between potentially modifiable exposures at baseline and incident AD independently diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria, or (2) a RCT targeting the impact of addressing modifiable risk factors on the incidence of AD or AD-related clinical endpoints (dementia or cognitive impairment), and (3) a publication written in English to permit easy access to the source information of all included articles. The detailed exclusion criteria are shown in figure 1. Bibliographies of relevant original studies and systematic reviews were hand-searched. Literature selection was performed by three pairs of experienced investigators (JTY, WX, CCT, HFW, MST and JQL) and any disagreements on inclusion were resolved by consensus and arbitration by a panel of investigators within the review team (JTY, WX, CCT, HFW, MST, JQL and Lan Tan).

Data extraction

Pre-designed templates were used to extract the data with reference to the STROBE statement (https://www.equator-network.org/reporting-guidelines/strobe/). An evidence-based profile of AD modifiable risk factors was established for better tracing of bias sources. The multivariable-adjusted risk estimates were extracted. If these estimates were unavailable, we attempted to obtain them by contacting the corresponding authors. The stringently performed process comprised three independent steps: (a) data extraction by three pairs of experienced investigators (JTY, WX, CCT, HFW, MST and JQL); (b) independent data proof reading by 10 researchers (JTY, WX, CCT, HFW, MST, JQL, XHH, YW, Lin Tan and Lan Tan); and (c) addressing discrepancies by consensus and arbitration.
Assessment of study quality and credibility of meta-analyses

The risk of bias tool proposed by Cochrane for RCTs and involving the Newcastle–Ottawa Quality Assessment Scale (NOS) for OPSs were used to evaluate the quality of eligible studies. The credibility of each result was then categorised into four levels: Good (G level), Acceptable (A± level), Susceptible (S± level) and Poor (P level) according to the score combination of three domains: risk of bias, inconsistency and imprecision. Levels of evidence were summarised, representing the quality of scientific evidence on the basis of directness of outcome for (RCTs), consistency and quality of data from clinical trials and/or observational studies. Classes of suggestions were made after weighing the benefits against the risks due to specific interventions. *Factors rated with ‘level C’ evidence were not considered for recommendation in the present study.

Levels of evidence and strength of suggestions

Levels of evidence were summarised to represent the quality of scientific evidence on the basis of directness of outcome for AD, credibility of meta-analyses and consistency of evidence from clinical trials and/or observational studies: Level A>Level B>Level C (based on the evidence level). Classes of recommendations were made after weighing the benefits against the risks due to specific interventions: Class I (strong recommendation), Class II (weak recommendation) and Class III (not recommended) (figure 2).

Statistical analyses

The multivariable-adjusted risk estimates and 95% confidence intervals (CI) were log-transformed and combined using random models (DerSimonian–Laird method). Sensitivity analyses excluding odd ratios (ORs) reported by some OPSs were performed because ORs tend to overestimate the effect size compared with the relative risk (RR), particularly when the incidence is not small. A 95% prediction interval (PI) was calculated to better evaluate the precision of the result. Heterogeneity was assessed by Q test and quantified by the I² metric. The source of heterogeneity was explored via sensitivity analyses, meta-regression and subgroup analyses. The robustness of the results was examined by excluding those rated as at a higher risk of bias. Publication bias was assessed following two steps: (1) testing the symmetry of the funnel plot by the Egger method; and (2) determining whether any asymmetry was due to publication bias via enhanced-contour funnel plots after the trim-and-fill method. The meta-regression and publication bias test were conducted only when at least 10 studies were available. The “metagen”, “metabias” and “trimfill” packages in R 3.4.3 software (https://www.r-project.org) were used to perform all the analyses.

Additionally, multiple subgroup and sensitivity analyses were conducted to take into account the following cases where results might be biased. First, 82% of studies recruited people without dementia at baseline and only 17% specifically constrained the population to those with normal cognition. Notably, inclusion of individuals with mild cognitive impairment, who might be at a prodromal stage of AD, resulted in a degree of misclassification bias, especially when the population was at an advanced age and was insufficiently followed. Thus, subgroup analyses according to the cognitive status at baseline (free of dementia vs cognitively normal), sufficiency of follow-up (online supplementary appendix 1) were conducted. Finally, life stage were performed. Second, it was often clinically difficult to distinguish mixed AD (coexistence of AD and vascular dementia (VD)) from VD among elderly people, especially when the pathological evidence is often unavailable and the individual has a history of stroke. Thus, to examine the influence of potential misclassification bias, subgroup analyses based on AD outcomes (all AD vs probable or pure AD (p-AD) defined as AD without VD or cerebrovascular disease (CVD)) were performed. Third, sensitivity analyses excluding studies with high attrition rates and poor generalisability (online supplementary appendix 1) were conducted.

Patient involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. Therefore, no patient or public involvement in this study is reported.
are no plans to disseminate the results of the research to study participants or the relevant patient community. No evaluation was undertaken to determine whether the studies included in the review had any patient involvement.

RESULTS

Figure 1 shows the flow diagrams of the study selection process for OPSs (figure 1A) and RCTs (figure 1B). The search yielded 33,145 and 11,531 records for OPSs and RCTs, respectively. After integration with the AlzRisk database and Clinicaltrials.gov website, a total of 243 OPSs and 153 completed RCTs were finally included. Evidence-based profiles were constructed (online supplementary appendix 3 & 4). The global distribution of studies eligible for the systematic review and their characteristics are shown in figure 1C. The sources of bias for the current evidence profile mainly consisted of generalisability, attrition and misclassification for OPSs and performance bias, incomplete outcome data, inadequate allocation concealment and selective outcome reporting for RCTs (online supplementary appendix figure 1).

Meta-analyses were conducted for 134 risk factors (online supplementary appendix 5). A total of 43 factors showed significant associations with the risk of AD, among which 80% were identified as significantly modifying the risk by at least 25% (figure 3A). Indicating the credibility of pooled results, analyses for eight risk factors (diabetes, orthostatic hypotension, hypertension in midlife, head trauma, stress, depression, midlife obesity and coronary artery bypass grafting (CABG) surgery) and three protective factors (cognitive activity, increased BMI in late life and education) were rated with moderate-to-high level credibility (G, G/A+ or A+ level). In addition, 20 factors were rated at a low-to-moderate level (A+/A− or A− level) and 12 were rated at a very low level (S+, S− or P level) (figure 3B). With good performance in all the domains above, eight factors were highlighted (figure 3C). AD, Alzheimer’s disease; BMD, bone mineral density; BMI, body mass index; CVD, cerebrovascular disease; DBP, diastolic blood pressure; HSV, herpes simplex virus; IMT, intima-media thickness; NSAIDs, non-steroidal anti-inflammatory drugs; SHBG, sex hormone binding globulin.

Figure 3 Risk of bias profile, meta-analysis results, sample size (figure 3A), credibility rating (figure 3B) and summary (figure 3C) for 43 significant modifiable risk factors based on observational prospective studies. When the mean score (for each bias domain) ≤0.5 was regarded as possibly moderate-to-high risk, analyses for 79% of factors had problems of generalisability, 60% for high attrition, 48% for insufficient follow-up, 40% for reverse causality, 8% for confounding bias and 6% for assessment of exposure. For a summary of the effect, a total of 43 factors showed significant associations with AD risk; 26 risk factors and eight protective factors were identified that modify the risk by at least 25% (figure 3A). For credibility of the pooled results, 11 factors were rated at a moderate-to-high level (G, G/A+ or A+ level), 20 were rated at a low-to-moderate level (A+/A− or A− level) and 12 were rated at a very low level (S+, S− or P level) (figure 3B). With good performance in all the domains above, eight factors were highlighted (figure 3C). AD, Alzheimer’s disease; BMD, bone mineral density; BMI, body mass index; CVD, cerebrovascular disease; DBP, diastolic blood pressure; HSV, herpes simplex virus; IMT, intima-media thickness; NSAIDs, non-steroidal anti-inflammatory drugs; SHBG, sex hormone binding globulin.

For RCTs, 29 metaanalyses covering 11 interventions were conducted (online supplementary appendix 6). Three interventions, including total homocysteine (tHcy)-lowering treatment (using folic acid, vitamin B12 and vitamin B6), cocoa flavanol and physical activity showed significant associations with AD or cognitive endpoints. For the directness of the outcomes, only five meta-analyses (including acetylcholinesterase inhibitor, antihypertensive treatment, non-steroidal anti-inflammatory drugs (NSAIDs), hormone replacement therapy and ginkgo biloba) examined associations with AD (figure 4A). For the levels of credibility, nine meta-analyses were rated at a moderate-to-high level (G, G/A+ or
A+ level), three were rated at a low-to-moderate level (A+/A− or A− level) and 17 were rated at a very low level (S+, S− or P level) (figure 4B). The overall evaluation highlighted two interventions that seemed promising (figure 4C): physical exercise (mini-mental state examination (MMSE), standardised mean difference (SMD) 0.28, 95% CI 0.07 to 0.50 and AD assessment scale cognition, SMD 0.25, 95% CI 0.08 to 0.41) and tHcy-lowering treatment (MMSE, SMD 0.09, 95% CI 0.02 to 0.15) (online supplementary appendix figure 3). Notably, oestrogen therapy was associated with an increase in the risk of dementia (G level).

The significance and the effect size minimally changed for most factors after excluding ORs (online supplementary appendix figure 4). No influences of publication bias on the pooled results were identified (online supplementary appendix 5). The sources of heterogeneity were explored. For diabetes (n=14, I² = 65%), the percentage of women explained 39% heterogeneity (p=0.008), which might be attributed to inclusion of two high-risk-of-bias studies24 25 that explored associations only for men. The mean age at baseline explained most heterogeneity for hypertension (p=0.0003) and BMI (p=0.091, τ² = 0). No influences of lowering the heterogeneity (I² < 10%) via sensitivity analyses on the pooled results were found for current smoking, systolic blood pressure, education and depression. The influence of risk of bias might be low for depression while smoking and stroke were vulnerable to sources of bias due to misclassification, attrition and generalisability (online supplementary appendix figure 5).

Twenty-one evidence-based suggestions with different levels of evidence (11 with Level A and 10 with Level B) and strength of suggestions (19 with Class I and two with Class III) are listed in table 1. Specifically, Class I suggestions were for 19 factors, including 10 factors with Level A evidence (cognitive activity, hyperhomocysteinaemia, increased BMI in late life, depression, stress, diabetes, head trauma, hypertension in midlife, orthostatic hypotension and education) and nine factors with Level B evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, CVD, frailty, atrial fibrillation and vitamin C) (figure 5). Two factors were not recommended (Class III): oestrogen replacement therapy (Level A) and acetylcholinesterase inhibitors (Level B) (online supplementary appendix 7 & appendix figure 6). Six factors (diastolic blood pressure management, NSAID use, social activity, osteoporosis, pesticide exposure and silicon from drinking water) were rated as Level C low-strength evidence, with the recommendation that their relationships with AD be confirmed in future studies.

**DISCUSSION**

Our systematic review and meta-analysis identified a total of 21 evidence-based suggestions that can be used in life-course...
practices to prevent AD. Nineteen were regarded as ‘strong suggestions’, nine of which were rated with Level A evidence (Table 1). Nearly two-thirds of these suggestions target vascular risk factors and lifestyle, strengthening the importance of keeping a good vascular condition and maintaining a healthy lifestyle for preventing AD.

**Strengths and weaknesses of this study**

This is the most comprehensive and large-scale systematic review and meta-analysis for AD prevention to date. The evidence-based suggestions are constructed by integrating a large amount of evidence from both OPSSs and RCTs. Sources of bias and robustness of evidence were thoroughly assessed and secondary analyses were used to explore their influences, guaranteeing the objectivity and transparency of our findings. Furthermore, the outcome of OPSSs was confined to AD dementia, given that the heterogeneity of endpoints might complicate the profile and downgrade the credibility of the evidence because: (1) observational studies are more vulnerable to sources of bias than RCTs, even though a rigorous procedure was employed to grade the evidence; (2) non-AD dementia accounts for roughly 30% of incident dementia (online supplementary appendix figure 7) and the false positive rate for diagnosis of mild cognitive impairment is fairly common.23 Some caveats should also be emphasised. Observational studies cannot indicate causal relationships and RCTs may not be generalisable beyond the specific sample, intervention, dose and duration studied. Classification of the available evidence including assessment of potential biases requires subjective judgement. The values of the current suggestions might be confined by geographic variability, definition of exposure and prevalence of risk factors at the population level. Some important factors of all-cause dementia were inadequately investigated for AD, such as social determinants27 and frailty,24 and more high-quality prospective studies are warranted to bridge this gap. AD is challenging to study. The neurobiology of AD begins at least 15 years before symptoms appear. Also, the content cannot be too detailed (especially for the dose and duration) for some factors and a very good trial is needed to replicate (pivotal studies). Also, these suggestions must be presented in the context of the limitations of the studies and continuing uncertainty among investigators.

**Table 1  Guideline for prevention of AD: preliminary clinical suggestions**

| Factors/interventions | Suggestion |
|-----------------------|------------|
| **Lifestyle**         |            |
| BMI and weight        | ▶ Adults aged <65 years should maintain or lose weight through an appropriate balance of physical activity, caloric intake and formal behavioural programmes when indicated to maintain/achieve a BMI between 18.5 and 24.9 kg/m² (Class I, level B) |
| management            | ▶ Adults aged >65 years should not to be too skinny (Class I, level A4) |
|                      | ▶ Adults aged >65 years with a trend of weight loss should be closely monitored for their cognitive status (Class I, level B) |
| **Physical exercise** | ▶ Individuals, especially those aged ≥65 years, should stick to regular physical exercise (Class I, Level B,*)
| **Cognitive activity**| ▶ Mentally stimulating activities should be encouraged, such as reading, playing chess, etc (Class I, level A4) |
| **Smoking**           | ▶ People should not smoke and should avoid environmental tobacco smoke. Counselling, nicotine replacement and other pharmacotherapy as indicated should be provided in conjunction with a behavioural programme or formal smoking cessation programme (Class I, Level B) |
| **Sleep**             | ▶ Get sufficient and good quality sleep and consult a doctor or receive treatment when you have problem with sleep (Class I, Level B) |
| **Comorbidities**     |            |
| **Diabetes**          | ▶ Stay away from diabetes via a healthier lifestyle and diabetic patients should be closely monitored for their cognitive decline (Class I, Level A4) |
| **CVD**               | ▶ Maintain a good condition of the cerebral vessels via a healthier lifestyle or medications to avoid atherosclerosis, low cerebral perfusion and any CVD. Individuals with stroke, especially cerebral microbleeding, should be carefully monitored for their cognitive change and take preventative measures as indicated to protect cognition (Class I, level B) |
| **Head trauma**       | ▶ Protect your head from injuries (Class I, level A4) |
| **Frailty**           | ▶ Stay healthy and strong in late life. Those with increasing frailty should be especially monitored for their cognition (Class I, level A4) |
| **Blood pressure**    | ▶ Individuals aged <65 years should avoid hypertension via a healthier lifestyle (Class I, Level A4) |
|                      | ▶ Individuals with DH should be closely monitored for their cognition (Class I, level A4) |
| **Depression**        | ▶ Maintain a good condition of mental health and closely keep an eye on the cognitive status for those with depressive symptoms (Class I, Level A4) |
| **AF**                | ▶ Maintain a good cardiovascular condition and manage AF using pharmaceuticals (Class I, level B) |
| **Stress**            | ▶ Relax your mind and avoid daily stress (Class I, Level A4) |
| **Other domains**     |            |
| **Education**         | ▶ Receive as much education as possible in early life (Class I, level A4) |
| **Hyperhomocysteinaemia** | ▶ Have a regular blood examination for homocysteine level. Individuals with hyperhomocysteinaemia should be treated with vitamin B and/or folic acid and be followed with a focus on their cognition (Class I, Level A2) |
| **Vitamin C**         | ▶ Vitamin C in the diet or taken as supplements might help (Class I, Level B) |
| **Not recommended**   |            |
| **ERT**               | ▶ Oestrogen replacement therapy should not be specifically used for AD prevention in postmenopausal women (Class III, Level A2) |
| **ACI**               | ▶ ACI should not be used for AD prevention in cognitively impaired individuals (Class III, Level B) |

*The risk of bias is rated as high mainly due to lack of a blinding method and allocation concealment, which however cannot be achieved in randomised controlled trials for interventions such as physical exercise. We therefore consider that the results are relatively more reliable than rated. Also, the content cannot be too detailed (especially for the dose and duration) for some factors and a very good trial is needed to replicate (pivotal studies). Also, these suggestions must be presented in the context of the limitations of the studies and continuing uncertainty among investigators.

ACI, acetylcholinesterase inhibitors; AF, atrial fibrillation; BMI, body mass index; CVD, cerebrovascular disease; ERT, estrogen replacement therapy; IMT, intima-media thickness; NSAIDs, non-steroidal anti-inflammatory drugs; OH, orthostatic hypotension.
Figure 5  Distribution of modifiable factors with Class I recommendation throughout the course of life. Class I suggestions (benefit >> risk due to intervention) risk factors include 10 factors with Level A evidence (cognitive activity, hyperhomocysteinaemia, increased BMI in late life, depression, stress, diabetes, head trauma, hypertension in midlife, orthostatic hypotension and education) and 9 factors (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, CVD, frailty, atrial fibrillation and vitamin C) with Level B evidence. The x axis represents the mean age of the total sample (solid circle) with a range of mean age (short horizontal line) for observational prospective studies included. The y axis represents the summary relative risk (RR).

Future research
For OPSs, low participation rates (cognitive activity and stroke), high attrition (stroke, smoking, alcohol drinking and hypertension) and follow-up insufficiency (stroke and smoking) should be specifically highlighted in future prospective studies. Reverse causality might bias the association with late life obesity. It is unclear whether reverse causality exists for other potential factors such as frailty, social isolation and sleep disorders. Investigation and comparison of important characteristics of those who refused to participate or were lost during follow-up might be a good method to guarantee optimised validity. Subgroup effects exist due to the characteristics of the sample (eg, age, gender, APOEε4 status and medication compliance) or exposure (eg, type, dose and duration). For RCTs, choosing the suitable population might be the key to determining whether an intervention can work. The optimal time window also matters, especially considering that benefits were weak for those with a clinical diagnosis of dementia. Generalisability should be further optimised, such as recruiting larger samples from community-dwelling individuals and searching for methods to lower dropout rates. Well-designed clinical trials are needed to verify the effects on AD of several promising interventions, including sleep improvement, smoking cessation, antidepressant management and antidiabetic agents.

CONCLUSIONS
Twenty-one clinical evidence-based suggestions are proposed, offering clinicians and stakeholders an evidence-based guideline...
for AD prevention. With credible though inconclusive evidence, the suggestions targeted 10 risk factors including diabetes, hyperhomocysteinaemia, poor BMI management, reduced education, hypertension in midlife, orthostatic hypotension, head trauma, less cognitive activity, stress and depression. This study provides an advanced and contemporary survey of the evidence, suggesting that more high-quality OPSs and RCTs are urgently needed to strengthen the evidence base for uncovering more promising approaches to preventing AD.

Author affiliations
1. Department of Neurology, Fudan University, Shanghai, China
2. Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
3. Department of Epidemiology and Public Health, University of Toulouse III, Toulouse, France
4. Department of Psychiatry, Medical Research Council and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
5. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
6. Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
8. Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China
9. Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
10. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing, China
11. Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
12. Department of Neurology, University Hospital of Montpellier, Montpellier, France
13. McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
14. Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, California, USA
15. Department of Geriatrics, Purpan University Hospital, Toulouse, France

Twitter Wei Xu @na and Can Zhang @martindragonc

Acknowledgements
The authors thank Professor Michael M Weiner and Dr Yu-Tzu Wu for critical review.

Contributors
JTY and BV conceived and designed the study, JTY, WX, CCT, HPW, MST and JQI selected the articles and extracted the data, JTY, WX, C-CT, HPW, M-ST, J-QL, XHH, YW, LT and LT proofread the data. JTY, WX, C-CT and AP analysed the data. WX and CCT generated the figures. JTY, WX, CCT wrote the first draft of the manuscript. JTY, WX, C-CT, SA, JE, EE, CQ, JJ, LF, EHK, YW, VM, JT, GS, PSA, QD, and BV interpreted the data and contributed to the writing of the final version of the manuscript. All authors agreed with the results and conclusions and approved the final draft.

Funding
This study was supported by grants from the National Key R&D Program of China (2018YFC1314702), Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX03) and ZHANGJ LAB.

Competing interests
JTY serves as an associate editor-in-chief for Annals of Translational Medicine and is an editorial board member for Journal of Alzheimer's Disease. SA has received grants from Europe, Ipsen, and France Alzheimer, served as a consultant for Ipsen, Pierre Fabre, Lilly, Nestlé, Sanofi and Servier, and received non-financial support from Biogen, Nutrition Santé, Pfizer and ICON, and other support from the AMPA Association. GS has received clinical trial support from Lilly and Roche in DIAN-TU, TauRx Therapeutics (TauRx) and Lundbeck; has been a data safety monitoring board (DSMB) member of ADCS, ATRI, API and Eisai; and has been a scientific adviser to Affiris, Boehringer Ingelheim, Lilly, Roche, Servier, Sanofi, Schwabe, Takeda and TauRx. PSA has received grants from the US Alzheimer’s Association, Janssen, Lilly, the US National Institute on Aging and Toyama; and consulting fees from Abbott, Abbvie, Amgen, Anavex, AstraZeneca, Biogen Idec, Biote, Bristol-Myers Squibb, Cardes, Cobaib, Eisai, Eli Lilly, Genentech, Ichor, Iberian, Janssen, Lundbeck, Medivation, Merck, NeuroPhage, Novartis, Pfizer, Piramidrup, Roche, Somirx and Toyama, outside the submitted work. BV reports grants from Pierre Fabre, Avid, Exonhit, AbbVie, Lilly, Lundbeck, MSD, Otsuka, Regenon, Sanofi, Roche, AstraZeneca, LPG Systems, Nestle and Alzheon, and personal fees from Lilly, Lundbeck, MSD, Otsuka, Roche, Sanofi, Biogen, Nestlé, Transition Therapeutics and Takeda.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Jin-Tai Yu http://orcid.org/0000-0002-7666-0547
Wei Xu http://orcid.org/0000-0002-3310-5875

REFERENCES
1 Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. *Neurology* 2013;80:1888–94.
2 Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382:1405–12.
3 Sattarzai CL, Beiser AS, Chouraki V, et al. Incidence of dementia over three decades in the Framingham Heart Study. *N Engl J Med* 2016;374:523–32.
4 Wu Y, Fratiglioni L, Matthews FE, et al. Dementia in Western Europe: epidemiological evidence and implications for policy making. *Lancet Neurol* 2016;15:116–24.
5 Andrieu S, Coley N, Lovestone S, et al. Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. *Lancet Neurol* 2015;14:926–44.
6 Livingston G, Sommerlad A, O RGQ C V, et al. Dementia prevention, intervention, and care. *Lancet* 2017;390:2673–74.
7 Winblad B, Amouyel P, Andreu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. *Lancet Neurol* 2016;15:455–532.
8 Mazure CM, Swendsen J. Sex differences in Alzheimer’s disease and other dementias. *Lancet Neurol* 2016;15:651–2.
9 Coley N, Andrieu S, Gardette V, et al. Dementia prevention: methodological explanations for inconsistent results. *Epidemiol Rev* 2008;30:35–66.
10 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8:336–41.
11 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-Analysis Of Observational Studies in Epidemiology* (MOOSE) group. *JAMA* 2000;283:2008–12.
12 Weuve JMM, Blacker D. The Alzheimer’s Disease: a review. Alzheimer research. Available: http://www.alzforum.org [Accessed [date of access].
13 McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* 1984;34:939–44.
14 Available: http://community.cochrane.org/editorial-and-publishing-policy-resource/cochrane-review-development/cochrane-handbooks-systematic-reviews-interventions
15 Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. *Health Technol Assess* 2003;7:27.
16 Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). *J Clin Epidemiol* 2011;64:407–15.
17 Guyatt GH, Oxman AD, kunz R, et al. GRADE guidelines 7. Rating the quality of evidence—insufficiency. *J Clin Epidemiol* 2011;64:1294–302.
18 Guyatt GH, Oxman AD, kunz R, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. *J Clin Epidemiol* 2011;64:1283–93.
19 Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
20 Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011;342:d549.
21 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
22 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
23 Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol* 2008;61:991–6.
24 Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. *Neurology* 2004;62:188–93.
25 Dal Forno G, Palemo MT, Donohue IE, et al. Depressive symptoms, sex, and risk for Alzheimer’s disease. *Ann Neurol* 2005;57:381–7.
26 Kopsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. *Neurology* 2012;79:1591–8.
27 Fratiglioni L, Wang HX, Ericsson K, et al. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet 2000;355:1315–9.
28 Stower H. Linking Alzheimer’s disease and frailty. Nat Med 2019;25:358.
29 Kane RL, Butler M, Fink HA, et al. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia. Rockville (MD). 2017.
30 Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255–63.
31 Donohue MC, Sperling RA, Petersen R, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017;317:2305–16.
32 Kivimäki M, Luukkonen R, Batty GD, et al. Body mass index and risk of dementia: analysis of individual-level data from 1.3 million individuals. Alzheimers Dement 2018;14:601–9.
33 Zissimopoulos JM, Barthold D, Brinton RD, et al. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol 2017;74:225–32.
34 Rajan KB, Barnes LL, Wilson RS, et al. BP and risk of incident AD dementia by antihypertensive and APOE epsilon4 allele. Ann Neurol 2018;83:935–44.
35 Kryscio RJ. Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. JAMA Neurol 2014;71:947–9.
36 Lamb SE, Sheehan B, Atherton N, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ 2018;361:k1675.